Inhibitory effect of several fluoroquinolones on hepatic microsomal cytochrome P-450 1A activities in dogs

被引:31
作者
Regmi, NL
Abd El-Aty, AM
Kuroha, M
Nakamura, M
Shimoda, M [1 ]
机构
[1] Tokyo Univ Agr & Technol, Dept Vet Med, Fac Agr, Tokyo 1838509, Japan
[2] Cairo Univ, Fac Vet Med, Dept Pharmacol, Giza, Egypt
关键词
D O I
10.1111/j.1365-2885.2005.00698.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We examined inhibitory effects of ofloxacin (OFX), orbifloxacin (OBFX), ciprofloxacin (CFX), enrofloxacin (EFX) and norfloxacin (NFX) on cytochrome P-450 1A (CYP1A) activities using hepatic microsomes from four beagle dogs. Ethoxyresorufin O-de-ethylation was referred as CYP1A activities. All the fluoroquinolones inhibited the reaction in a noncompetitive manner. The determined inhibitory constants were the followings; 10.1 +/- 3.8 mM for OFX, 6.43 +/- 2.01 mM> for OBFX, 0.726 +/- 0.134 mM for CFX, 4.06 +/- 1.19 mM for EFX and 4.75 +/- 1.63 mM for NFX respectively. As these values are > 100-fold of plasma concentrations after a clinical single dose of the fluoroquinolones, it is suggested that the inhibitory effect on CYP1A activities is not so high to elicit drug-drug interaction with CYP1A substrates, when these fluoroquinolones are co-administered. Mechanism based inhibition was also examined in this study. Of the five fluoroquinolones examined, OFX, OBFX and CFX had this inhibition manner. As this inhibition is irreversible, inhibitory effects of the three fluoroquinolones may accumulate, when they are repeatedly administered. Therefore, OFX, OBFX and CFX may result in substantial drug-drug interaction with a CYP1A substrate even in clinical states. As EFX is metabolized to CFX in the body, it may also have the same possibility.
引用
收藏
页码:553 / 557
页数:5
相关论文
共 19 条
[11]   Effect of multiple dosing of ketoconazole on pharmacokinetics of midazolam, a cytochrome P-450 3A substrate in beagle dogs [J].
Kuroha, M ;
Azumano, A ;
Kuze, Y ;
Shimoda, M ;
Kokue, E .
DRUG METABOLISM AND DISPOSITION, 2002, 30 (01) :63-68
[12]  
McLellan RA, 1996, DRUG METAB DISPOS, V24, P1134
[13]  
OMURA T, 1964, J BIOL CHEM, V239, P2370
[14]  
Saitoh T, 1999, J VET PHARMACOL THER, V22, P87, DOI 10.1046/j.1365-2885.1999.00195.x
[15]  
VANDERHO.TA, 1974, J BIOL CHEM, V249, P6302
[16]   Interaction of norfloxacin with divalent and trivalent pharmaceutical cations. In vitro complexation and in vivo pharmacokinetic studies in the dog [J].
Wallis, SC ;
Charles, BG ;
Gahan, LR ;
Filippich, LJ ;
Bredhauer, MG ;
Duckworth, PA .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1996, 85 (08) :803-809
[17]   THE INFLUENCE OF QUINOLONE DERIVATIVES ON THEOPHYLLINE CLEARANCE [J].
WIJNANDS, WJA ;
VREE, TB ;
VANHERWAARDEN, CLA .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 22 (06) :677-683
[18]   A non-arthropathic dose and its disposition following repeated oral administration of ofloxacin, a new quinolone antimicrobial agent, to juvenile dogs [J].
Yabe, K ;
Murakami, Y ;
Nishida, S ;
Sekiguchi, M ;
Furuhama, K ;
Goryo, M ;
Okada, K .
JOURNAL OF VETERINARY MEDICAL SCIENCE, 2001, 63 (08) :867-872
[19]   A PHARMACOKINETIC ANALYSIS PROGRAM (MULTI) FOR MICROCOMPUTER [J].
YAMAOKA, K ;
TANIGAWARA, Y ;
NAKAGAWA, T ;
UNO, T .
JOURNAL OF PHARMACOBIO-DYNAMICS, 1981, 4 (11) :879-885